학술논문
Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland
Document Type
article
Author
Kathrin Perrig; Niklas Krupka; Sebastian Bruno Ulrich Jordi; Jean-Benoît Rossel; Luc Biedermann; Thomas Greuter; Philipp Schreiner; Stephan R. Vavricka; Pascal Juillerat; Emanuel Burri; Dorothee Zimmermann; Michel H. Maillard; Michael Christian Sulz; Stephan Brand; Gerhard Rogler; Benjamin Misselwitz
Source
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Subject
Language
English
ISSN
1756-2848
17562848
17562848
Abstract
Background: Tumor necrosis factor (TNF) inhibitors have improved treatment of ulcerative colitis (UC), but loss of response remains a frequent problem. The anti-TNF agent, golimumab, was approved in Switzerland for the treatment of UC in 2014. This study aims to summarize the experience of golimumab in a real-world setting in Switzerland. Methods: We analyzed real-world data from 1769 UC patients from the Swiss Inflammatory Bowel Disease Cohort (SIBDC) study and performed a chart review of golimumab-treated patients. We extracted the partial Mayo score at t 0 (baseline), t 1 (2–16 weeks), t 2 (17–35 weeks), and t 3 (36–89 weeks). The primary endpoint was clinical response at t 1 , defined as marked improvement in partial Mayo score and objective parameters. Clinical remission was defined as resolution of symptoms and normalization of objective parameters. Results: Our chart review included 103 UC patients with golimumab treatment (5.8% of all SIBDC UC patients); only 16 (15.5%) were anti-TNF naïve. Sixty-three patients remained on golimumab (61.2%) after 180 days, 51 (44.7%) after 365 days, and 34 (33%) after 630 days after the start of treatment. Upon golimumab treatment, the partial Mayo score decreased from 4 [interquartile range (IQR): 2–6] at t 0 to 2 (IQR: 0–4) at t 1 , 1 (IQR: 0–3.5) at t 2 , and 1 (IQR: 0–3) at t 3 ( p